Lanzhou Foci Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.48B, placing it among publicly traded companies globally. Its enterprise value stands at 2.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A has 510.66M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.88, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A recorded 19.40M in income tax expense.

As of the close on October 23, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A's stock has declined approximately 14.88% over the past 52 weeks. The 50-day moving average sits at 8.32, while the 200-day moving average is 8.30.

As of June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A holds 634.61M in cash and equivalents against 31.80M in total debt, resulting in a net debt position of -607.66M. Total book value stands at 1.86B, with working capital of 928.53M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Lanzhou Foci Pharmaceutical Co., Ltd. Class A paid dividends of 0.02 per share.

Lanzhou Foci Pharmaceutical Co., Ltd. Class A's most recent stock split took place on August 14, 2015 with a 2:5 split ratio.